This executive spotlight article is a dedicated Q & A with MERIT’s CEO and Co-founder, Yijun Huang.
What is your vision for MERIT?
My vision for MERIT is to be the most trusted and impactful imaging endpoint partner in drug development. We aim to help biotech and pharmaceutical companies generate high-quality, decision‑ready data that accelerates development, reduces risk, and ultimately brings effective therapies to patients faster. MERIT is not just a service provider—we strive to be a long‑term collaborator across the full lifecycle of clinical development.
What is MERIT’s competitive advantage as an endpoint solution provider?
MERIT’s competitive advantage is built on four pillars of success:
- Scientific Rigor – Deep expertise in imaging science, biomarkers, and regulatory-grade endpoints ensures data credibility and consistency across trials.
- Technology & Innovation – A robust, evolving imaging platform, EXCELSIORTM, developed by an in‑house engineering team, enabling scalable, high‑quality data processing.
- Operational Excellence – Proven global execution capabilities with a strong track record of on-time, high‑quality trial delivery.
- Partnership Mindset – We work as an extension of our clients’ teams, offering flexibility, transparency, and true collaboration.
Together, these pillars allow MERIT to deliver reliable endpoints while adapting to each client’s unique development strategy.
How is MERIT positioned in the competitive CRO market?
MERIT operates within a sphere of collaboration rather than competition. We partner seamlessly with sponsors, CROs, technology providers, and academic groups. This positioning allows us to stay focused on what we do best—imaging endpoints—while fitting naturally into broader development ecosystems. Our independence and collaborative approach make us a preferred partner in complex, multi‑vendor trials.
How does AI affect MERIT?
AI enhances MERIT’s ability to deliver scalable, high‑quality imaging solutions. We leverage AI and advanced analytics to improve image processing efficiency, consistency, and insight generation. Importantly, AI at MERIT is used to augment scientific expertise, not replace it—ensuring that automation strengthens accuracy, speed, and decision‑making while remaining grounded in clinical and regulatory requirements.
How would you define MERIT’s company culture?
MERIT’s culture is collaborative, mission‑driven, and grounded in helping biotech companies succeed. We value teamwork, scientific integrity, and mutual respect. Internally, we encourage ownership and cross‑functional collaboration; externally, we are deeply committed to supporting our clients as true partners in drug development.
How would you describe the growth of MERIT?
MERIT has experienced consistent, sustained growth year-over-year for more than a decade. We have been recognized on the Inc. 5000 list for eight consecutive years, demonstrating not only expansion but durable performance. This growth reflects increasing demand for high-quality imaging endpoints and the long-term trust our clients place in us.
What has changed about your role as the company has scaled?
In the early days, I was deeply involved in hands‑on execution, including coding and system development. As MERIT has grown, my role has evolved. Today, I focus on three core responsibilities:
- Setting the strategic direction of the company
- Hiring and empowering the best talent
- Maintaining and protecting MERIT’s culture
Our talented teams now lead technology and operations, allowing me to concentrate on long‑term vision and sustainable growth.